BOLD
Boundless Bio, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$32.35M
P/E Ratio
—
EPS
$-2.49
Beta
0.95
52W High
$1.68
52W Low
$0.96
50-Day MA
$1.36
200-Day MA
$1.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Boundless Bio, Inc. Common Stock
Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare diseases caused by single gene defects. The company is headquartered in San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-59.47M |
| Operating Margin | 0.00% |
| Return on Equity | -50.20% |
| Return on Assets | -22.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.85 |
| Price-to-Book | 0.37 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $22.46M |
| Float | $15.33M |
| % Insiders | 11.36% |
| % Institutions | 49.77% |
Historical Volatility
HV 10-Day
57.94%
HV 20-Day
55.06%
HV 30-Day
92.08%
HV 60-Day
71.15%
HV Rank
91.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($4.00 target)
2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026